TAVI for aortic regurgitation – India's first case with Corevalve Evolut R

Abstract

Transcatheter Aortic Valve Implantation (TAVI) is a well-described treatment for symptomatic calcific severe aortic stenosis. However, TAVI technology is being increasingly used around the world to treat selected cases of severe aortic regurgitation (AR). One of the main limitations of using TAVI technology for AR is the lack of calcification, which is common in such cases. This makes anchoring of a TAVI prosthesis to the aortic annulus difficult and risks displacement or embolization. However, with the availability of recapturable and repositionable TAVI technologies, these limitations have been overcome to a large extent. This is the first Corevalve Evolut R device that was used in India and the first TAVI to treat AR in India.

Transfemoral transcatheter aortic valve replacement via TEE guiding in a severe aortic regurgitation with Stanford type B aortic dissection：A case report

“…As the population continues to age, there will be more patients with complex aortic disease. There have been many cases to prove the application of TAVR technology in special conditionsIn [5][6]. In this case, we demonstrates that transfemoral TAVR via TTE for AR patients with chronic type B dissection is a feasible choice.…”

Transcatheter aortic valve replacement for aortic regurgitation in Asians

“…Only one full report 12 recorded the AR aetiology of its included patients, with the majority of cases due to degeneration (72.1%) with rheumatic heart disease (23.2%) and bicuspid aortic valve (4.7%) accounting for the remainder of the cases. Two case reports 13,14 also recorded AR aetiology, both secondary to infective endocarditis. None of the studies or case reports reported other aortic valve characteristics such as valve calcification or shape.…”